Parkinson's disease (PD) is a motor disorder characterized by dopaminergic and noradrenergic dysfunction, culminating in motor symptoms in non-motor ones. Chronic use of beta-blockers has been associated with an increased risk of PD, but this association may be a causal effect. We evaluated the effect of chronic propranolol administration on motor, non-motor, and immunoreactive changes in a reserpine-induced parkinsonism model. Wistar rats were subjected to chronic administration of propranolol, 10, 20, or 40 mg/kg, subcutaneously (s.c.) daily, for 60 days (CEUA: 6294030423). After 30 days of experimentation, the animals were induced to parkinsonism with reserpine 0.1 mg/kg, s.c. injection every 48h, subjected to behavioral tests and immunohistochemistry for tyrosine hydroxylase (TH). Propranolol, dose-dependently, attenuated the motor impairment in catalepsy and increased the rearing time at a dose of 10 mg/kg. Furthermore, doses of 10 and 40 mg/kg promoted a decrease in oral tremor time and the number of vacuous chewing, and only the 10 mg/kg dose improved the animals' working memory. Conversely, propranolol 20 and 40 mg/kg increased TH immunoreactivity in the SNpc, and only the 40 mg/kg dose in the VTA. Thus, propranolol may alleviate motor deficits and protect against dopaminergic depletion induced by reserpine. Studies are needed to understand the pathophysiological and neuroprotective mechanisms of propranolol associated with PD.